目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 25)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY
1.6 RESEARCH LIMITATIONS
1.7 STAKEHOLDERS
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH DATA
FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 4 MARKET SIZE, 2023 (USD MILLION)
FIGURE 5 MARKET: FINAL CAGR PROJECTIONS (2023−2029)
FIGURE 6 MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION AND TRIANGULATION
2.3.1 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
2.6 MARKET: GLOBAL RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 38)
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
FIGURE 9 MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)
FIGURE 10 MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)
FIGURE 11 MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 41)
4.1 HUMAN MICROBIOME MARKET OVERVIEW
FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
4.2 NORTH AMERICA: MARKET,BY APPLICATION AND COUNTRY (2023)
FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
4.3 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research
5.2.1.2 Surging demand for personalized medicine
5.2.1.3 Rising awareness about importance of human microbiome
5.2.2 RESTRAINTS
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes
5.2.3 OPPORTUNITIES
5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies
TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 Slow patient adoption of microbiome-based therapies
5.2.4.2 Complexities involved in development of microbiome therapies
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 SUPPLY AND VALUE CHAIN ANALYSIS
5.5.1 MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 17 MARKET: SUPPLY CHAIN ANALYSIS
5.5.2 VALUE CHAIN ANALYSIS OF MARKET
FIGURE 18 MARKET: VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 19 MARKET: ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
5.10 KEY CONFERENCES AND EVENTS IN 2023
5.10.1 HUMAN MICROBIOME CONFERENCES (2023)
TABLE 12 HUMAN MICROBIOME CONFERENCES (2023)
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 20 MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
5.11.2 MARKET: BUYING CRITERIA
FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS

6 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. - 61)
6.1 INTRODUCTION
TABLE 13 MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
6.2 THERAPEUTICS
6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET
TABLE 14 MARKET FOR THERAPEUTICS, BY REGION, 2023-2029 (USD MILLION)
TABLE 15 NORTH AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 16 EUROPE: MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC: MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
6.3 DIAGNOSTICS
6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 18 MARKET FOR DIAGNOSTICS, BY REGION, 2023-2029 (USD MILLION)
TABLE 19 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 20 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)

7 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. - 68)
7.1 INTRODUCTION
TABLE 22 MARKET, BY DISEASE, 2023-2029 (USD MILLION)
7.2 INFECTIOUS DISEASES
7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET
TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 24 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2029 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
7.3 GASTROINTESTINAL DISEASES
7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET
TABLE 28 MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2029 (USD MILLION)
TABLE 29 NORTH AMERICA: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 30 EUROPE: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
7.4 ENDOCRINE & METABOLIC DISORDERS
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET
TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS
TABLE 33 MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2029 (USD MILLION)
TABLE 34 NORTH AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 35 EUROPE: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
7.5 CANCER
7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET
TABLE 37 MARKET FOR CANCER, BY REGION, 2023-2029 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 39 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 40 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
7.6 OTHER DISEASES
TABLE 41 MARKET FOR OTHER DISEASES, BY REGION, 2023-2029 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 43 EUROPE: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. - 80)
8.1 INTRODUCTION
TABLE 45 MARKET, BY PRODUCT, 2023-2029 (USD MILLION))
8.2 DRUGS
8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET
TABLE 46 MARKET FOR DRUGS, BY REGION, 2023-2029 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 48 EUROPE: MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
8.3 DIAGNOSTIC TESTS
8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET
TABLE 50 MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023-2029 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
8.4 PROBIOTICS
8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY
TABLE 54 MARKET FOR PROBIOTICS, BY REGION, 2023-2029 (USD MILLION)
TABLE 55 NORTH AMERICA: MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 56 EUROPE: MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 57 ASIA PACIFIC: MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
8.5 PREBIOTICS
8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
TABLE 58 MARKET FOR PREBIOTICS, BY REGION, 2023-2029 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 60 EUROPE: MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
8.6 OTHER PRODUCTS
TABLE 62 MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
TABLE 63 NORTH AMERICA: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 64 EUROPE: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 65 ASIA PACIFIC: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY TYPE (Page No. - 92)
9.1 INTRODUCTION
TABLE 66 MARKET, BY TYPE, 2023-2029 (USD MILLION)
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
TABLE 67 MARKET FOR BCT/FMT, BY REGION, 2023-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 69 EUROPE: MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
9.3 PEPTIDES
9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET
TABLE 71 MARKET FOR PEPTIDES, BY REGION, 2023-2029 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
9.4 LIVE BIOTHERAPEUTIC PRODUCTS
9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
TABLE 75 MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 77 EUROPE: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
9.5 OTHER TYPES
TABLE 79 MARKET FOR OTHER TYPES, BY REGION, 2023-2029 (USD MILLION)
TABLE 80 NORTH AMERICA: MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 81 EUROPE: MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 82 ASIA PACIFIC: MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY REGION (Page No. - 101)
10.1 INTRODUCTION
FIGURE 22 MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)
TABLE 83 MARKET, BY REGION, 2023-2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 84 NORTH AMERICA: MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.2.1 US
10.2.1.1 Spike in research activities to drive market
TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 89 US: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 90 US: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 91 US: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research
TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 93 CANADA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 94 CANADA: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 95 CANADA: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 97 EUROPE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 98 EUROPE: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 99 EUROPE: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Rapid increase in government funding to propel market
TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 101 GERMANY: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 102 GERMANY: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 103 GERMANY: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.3.2 UK
10.3.2.1 Significant government investments in genomics research to propel growth
TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 105 UK: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 106 UK: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 107 UK: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rise in microbiome sequencing startups to boost growth
TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE
TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 110 FRANCE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 111 FRANCE: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 112 FRANCE: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.3.4 REST OF EUROPE
TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 114 REST OF EUROPE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 115 REST OF EUROPE: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 116 REST OF EUROPE: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.3.5 EUROPE: IMPACT OF RECESSION
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 117 ASIA PACIFIC: MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
TABLE 118 ASIA PACIFIC: MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 120 ASIA PACIFIC: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 121 ASIA PACIFIC: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing R&D investments to drive growth
TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 123 CHINA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 124 CHINA: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 125 CHINA: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Growing geriatric population to present opportunities for market growth
TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 127 JAPAN: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 128 JAPAN: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 129 JAPAN: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing prevalence of chronic diseases to support growth
TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 131 INDIA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 132 INDIA: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 133 INDIA: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 135 REST OF ASIA PACIFIC: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 136 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 137 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 REST OF THE WORLD
TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
TABLE 139 REST OF THE WORLD: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 140 REST OF THE WORLD: MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
TABLE 141 REST OF THE WORLD: MARKET, BY TYPE, 2023-2029 (USD MILLION)
10.5.1 REST OF THE WORLD: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE (Page No. - 134)
11.1 INTRODUCTION
11.2 KEY STRATEGIES ADOPTED BY PLAYERS
FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 COMPANY EVALUATION QUADRANT
FIGURE 26 MARKET: COMPANY EVALUATION MATRIX (2022)
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
FIGURE 27 MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)
11.4.5 COMPETITIVE BENCHMARKING
11.4.5.1 market: Detailed list of start-ups/SMEs
TABLE 142 MARKET: DETAILED LIST OF START-UPS/SMES
11.4.5.2 market: Competitive benchmarking of key players (start-ups/SMEs)
TABLE 143 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
11.5 COMPETITIVE SCENARIO AND TRENDS
TABLE 144 MARKET: DEALS
11.5.1 PRODUCT LAUNCHES
TABLE 145 MARKET: PRODUCT LAUNCHES
11.5.2 EXPANSIONS
TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS

12 COMPANY PROFILES (Page No. - 145)
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS
12.1.1 SERES THERAPEUTICS, INC.
TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW
12.1.2 ENTEROME
TABLE 148 ENTEROME: COMPANY OVERVIEW
12.1.3 4D PHARMA PLC
TABLE 149 4D PHARMA: COMPANY OVERVIEW
FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022)
12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)
12.1.5 OPTIBIOTIX HEALTH PLC
TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW
FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021)
12.1.6 FERRING PHARMACEUTICALS
TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW
12.1.7 SYNLOGIC, INC.
TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW
FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022)
12.1.8 SECOND GENOME INC.
TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW
12.1.9 VEDANTA BIOSCIENCES, INC.
TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW
12.1.10 YSOPIA BIOSCIENCE
TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW
12.1.11 FLIGHTPATH BIOSCIENCES, INC.
TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW
12.1.12 FINCH THERAPEUTICS GROUP, INC.
TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW
FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)
12.1.13 AOBIOME THERAPEUTICS
TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW
12.1.14 BIOGAIA
TABLE 160 BIOGAIA: COMPANY OVERVIEW
FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021)
12.1.15 QUANTBIOME, INC. (DBA OMBRE)
TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW
12.2 OTHER PLAYERS
12.2.1 VIOME LIFE SCIENCES, INC.
12.2.2 BIOHM HEALTH
12.2.3 DAYTWO
12.2.4 ALTAS BIOMED
12.2.5 BIONE VENTURES PRIVATE LIMITED
12.2.6 LUXIA SCIENTIFIC
12.2.7 METABIOMICS
12.2.8 SUN GENOMICS
12.2.9 SEED HEALTH
12.2.10 GNUBIOTICS SCIENCES
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.?

13 APPENDIX (Page No. - 183)
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.2 CUSTOMIZATION OPTIONS
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS